Therapeutic apheresis in special populations

Journal of Clinical Apheresis

Volumn 25, Issue 5, 2010, Pages 265-274

  Balogun, Rasheed A ^a   Ogunniyi, Adesola ^b   Sanford, Kimberly ^c   Okafor, Chidi ^a   Lobo, Peter I ^a   Siami, Ghodrat ^d   Barcia, John ^f   Kaplan, Andre A ^e  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

apheresis; plasmapheresis; therapeutic plasma exchange

Indexed keywords

APHERESIS; ARTICLE; CRITICALLY ILL PATIENT; CYTAPHERESIS; IMMUNOADSORPTION; KIDNEY TRANSPLANTATION; PHLEBOTOMY; PLASMAPHERESIS; TREATMENT INDICATION; BLOOD; CRITICAL ILLNESS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISOLATION AND PURIFICATION; REVIEW;

CALCIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM;

BLOOD COMPONENT REMOVAL; CALCIUM; CHOLESTEROL, LDL; CRITICAL ILLNESS; HUMANS; IMMUNOSORBENT TECHNIQUES; KIDNEY TRANSPLANTATION; MAGNESIUM; PLASMA EXCHANGE; PLASMAPHERESIS;

EID: 79952197293     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20250     Document Type: Article

References (37)

1. Kale-Pradhan PB, Woo MH,. A review of the effects of plasmapheresis on drug clearance. Pharmacotherapy 1997; 17: 684-695. (Pubitemid 27318962)
2. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shah BH, Weinstein R, Wirk A, Winters JL,. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22: 106-175. (Pubitemid 47025120)
3. Aydemir S, Ustundag Y, Bayraktaroglu T, Tekin IO, Peksoy I, Unal AU,. Fulminant hepatic failure associated with propylthiouracil: a case report with treatment emphasis on the use of plasmapheresis. J Clin Apher 2005; 20: 235-238.
4. Vaquero J, Butterworth RF,. Mechanisms of brain edema in acute liver failure and impact of novel therapeutic interventions. Neurol Res 2007; 29: 683-690. (Pubitemid 350086067)
5. Clemmesen JO, Kondrup J, Nielsen LB, Larsen FS, Ott P,. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol 2001; 96: 1217-1223. (Pubitemid 32319164)
6. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL,. The new approach to assignment of ASFA categories-introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007; 22: 96-105. (Pubitemid 47025119)
7. Davenport RD,. Therapeutic apheresis. In:, Roback JD, Combs MR, Grossman BJ, Hillyer CD, editors. Technical Manual. Bethesda, MD: AABB Press. 2008. pp 697-713.
8. Oh MS,. Evaluation of renal function,water, electrolytes and acid-base balance. In:, McPherson RA, Pincus MR, editors. Henry's Clinical Diagnosis and Management by Laboratory Methods. Philadelphia, PA: WB Saunders. 2007. pp 147-169.
9. Weinstein R,. Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange. J Clin Apher 2001; 16: 210-211. (Pubitemid 34037611)
10. Haddad S, Leitman SF, Wesley RA, Cecco S, Yau YY, Starling J, Rehak NN, Bolan CD,. Placebo-controlled study of intravenous magnesium supplementation during large-volume leukapheresis in healthy allogeneic donors. Transfusion 2005; 45: 934-944. (Pubitemid 40798785)
11. Jones HG, Bandarenko N,. Management of the therapeutic apheresis patient. In:, McLeod BC, editor. Apheresis Principles and Practice. Bethesda, MD: AABB Press. 2003. pp 253-274.
12. Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ,. Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 2007; 27: 1529-1549. (Pubitemid 350060208)
13. Crookston KP, Simon TL,. Physiology of apheresis. In:, McLeod BC, editor. Apheresis Principles and Practice. Bethesda, MD: AABB Press. 2003. pp 71-93.
14. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC,. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736-740. (Pubitemid 37174468)
15. Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, Morrin P, Posen G, Bernstein K,. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992; 20: 261-269.
16. Kaplan AA,. Therapeutic plasma exchange for the treatment of rapidly progressive glomerulonephritis. Ther Apher 1997; 1: 255-259. (Pubitemid 127685369)
17. Turnberg LA, Mahoney MP, Gleeson MH, Freeman CB, Gowenlock AH,. Plasmaphoresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis. Gut 1972; 13: 976-981.
18. Stamler J, Wentworth D, Neaton JD,. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-2828. (Pubitemid 17178359)
19. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA,. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-1707. (Pubitemid 20231527)
20. Thompson GR, Lowenthal R, Myant NB,. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975; 1: 1208-1211.
21. Kroon AA, van Asten WN, Stalenhoef AF,. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996; 125: 945-954. (Pubitemid 26424522)
22. Suckfull M,. Hearing Loss Study G: Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomized multicenter trial. Lancet 2002; 360: 1811-1817. (Pubitemid 35449418)
23. Siami GA, Siami FS,. Membrane plasmapheresis in the United States: a review over the last 20 years. Ther Apher 2001; 5: 315-320. (Pubitemid 33062681)
24. Siami FS, Siami GA,. Cryofiltration apheresis in the treatment of cryoprecipitate induced diseases. Ther Apher 1997; 1: 58-62. (Pubitemid 127685778)
25. Siami GA, Siami FS,. Current topics on cryofiltration technologies. Ther Apher 2001; 5: 283-286. (Pubitemid 33062676)
26. Siami GA, Siami FS,. Cryofiltration apheresis in the United States. Ther Apher 1998; 2: 228-235. (Pubitemid 28402328)
27. Siami GA, Siami FS,. Intensive tandem cryofiltration apheresis and hemodialysis to treat a patient with severe calciphylaxis, cryoglobulinemia, and end-stage renal disease. ASAIO J 1999; 45: 229-233.
28. Abel JJ, Rowntree LG, Turner BB,. Plasma removal with return of corpuscles (plasmaphaeresis). J Pharmacol Exp Ther 1914; 5: 625-641.
29. Shumak KH, Rock GA,. Therapeutic plasma exchange. N Engl J Med 1984; 310: 762-771. (Pubitemid 14161409)
30. World Health Organization. Country Health System Fact Sheet 2006: Nigeria: World Health Statistics, 2008.
31. Abjah UM, Aken'Ova YA, Ocheni S,. Waldenstrom's macrogloblinaemia: modified plasmapheresis as treatment option in a Nigeria setting. Niger J Med 2002; 11: 190-192.
32. Talabi OA, Abjah UM, Ocheni S, Akinyemi OA, Aken'ova YA, Ogunniyi A,. Benefit of modified plasmapheresis in the management of myasthenia gravis: a case report. Niger J Med 2006; 15: 162-164.
33. Olasunkanmi FO, Aken'Ova YA,. Guillain-Barre syndrome in a haemoglobin S patient. Afr J Med Med Sci 2005; 34: 189-191.
34. Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, Sutton DM,. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131: 453-462. (Pubitemid 29444437)
35. Anonymous. Appropriate number of plasma exchanges in Guillain-Barre syndrome: The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 1997; 41: 298-306.
36. Schwab PJ, Fahey JL,. Treatment of Waldenstrom's macroglobulinemia by plasmapheresis. N Engl J Med 1960; 22: 574-579.
37. Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates PT,. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol 2009; 70: 595-599.